Sanctuary Advisors LLC Invests $2.96 Million in DexCom, Inc. $DXCM

Sanctuary Advisors LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 44,017 shares of the medical device company’s stock, valued at approximately $2,965,000.

Other institutional investors have also added to or reduced their stakes in the company. Reflection Asset Management bought a new position in DexCom during the 4th quarter worth about $25,000. Ascentis Independent Advisors bought a new stake in shares of DexCom in the first quarter valued at about $25,000. MCF Advisors LLC bought a new stake in shares of DexCom in the fourth quarter valued at about $32,000. Wellington Grp LLC boosted its position in shares of DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares during the period. Finally, DV Equities LLC acquired a new position in shares of DexCom during the fourth quarter worth about $36,000. 97.75% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,035 shares of company stock worth $5,446,673 in the last three months. 0.28% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent research reports. Truist Financial set a $93.00 target price on DexCom and gave the company a “buy” rating in a research report on Friday, July 31st. Benchmark raised their price target on shares of DexCom from $77.00 to $82.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a report on Friday, May 15th. TD Cowen reiterated a “buy” rating on shares of DexCom in a report on Friday, July 31st. Finally, Weiss Ratings raised shares of DexCom from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

DexCom Stock Performance

Shares of DXCM opened at $89.16 on Wednesday. The firm has a 50-day moving average of $78.15 and a 200-day moving average of $71.19. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The company has a market cap of $33.65 billion, a PE ratio of 35.24, a price-to-earnings-growth ratio of 1.54 and a beta of 1.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the business earned $0.48 EPS. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. As a group, equities analysts forecast that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.